A comparative study of tazobactam/piperacillin and piperacillin in bacterial pneumonia

Kotaro Oizumi; Takayosi Ohno; Masao Kawahara; Shinzo Kawaguchi; Masazumi Saisho; Yoshiyuki Mitutake; Akira Saito; Masumi Tomizawa; Takao Koike; Kazuo Takebe; Toyokazu Tamura; Hiroshi Inoue; Kazuki Konishi; Takashi Mohri; Sakura Katoh; Kenichi Takeuchi; Akiho Ohara; Haruhito Hirano; Hideki Ikeda; Kunio Sirato; Yasuo Tanno; Masato Tohno; Yasuo Ono; Takuya Suzuki; Masahiro Sakamoto; Akira Watanabe; Toshihiro Nukiwa; Kiyoshi Konno; Kuniharu Shida; Tsuneo Sayama; Kazuo Sato; Yoshiyuki Anzai; Yoshiki Anazawa; Susumu Yoshida; Akira Ohishi; Kohtaro Kaneko; Kaoru Shimada; Yasuyuki Sano; Norihisa Akiyama; Yasuo Arai; Mamoru Ohtomo; Koichiro Nakada; Tatsuo Nakatani; Naohiko Tyonabayashi; Koichiro Kudo; Hiroko Arioka; Harumi Shishido; Atsushi Takahashi; Atsuhisa Tamura; Hirofumi Katayama; Motoo Baba; Masaru Koyama; Kohji Murabayashi; Jingoro Shimada; Shoichiro Irimajiri; Yasuo Matsuoka; Mitsuo Obana; Fumio Matsumoto; Takeo Imai; Shigeki Odagiri; Takashi Oguri; Yoshihiro Hirai; Masaaki Arakawa; Shigeyuki Hoshino; Hiroki Tsukada; Nobuki Aoki; Saburo Izumi; Atsuhiko Sato; Tadakazu Hattori; Yutaka Nakano; Kenzo Takagi; Yasunobu Noda; Hideo Gonda; Toshihiko Takeuchi; Yasuo Yamada; Hidekazu Hanaki; Makoto Kawakami; Toshiyuki Yamamoto; Kanzo Suzuki; Toshinobu Yamamoto; Fumiyuki Kuze; Kenji Bando; Shinichiro Ohyama; Shohei Kusaka; Tadashi Ishida; Yoshiro Mochizuki; Rieko Kanan; Kazushige Tsuyuguchi; Kojiro Yasunaga; Seibun Yonezu; Yoshitaka Yamanaka; Nobuhiro Narita; Masayoshi Sawaki; Keiichi Mikasa; Kazuya Higashino; Takashi Nakano; Tetsuya Nishigaki; Yumiko Goto; Hiroshi Sugimoto; Rinzo Soejima; Yoshihito Niki; Osamu Moriya; Akihisa Shindo; Toshiharu Matsushima; Makoto Kimura; Michio Yamakido; Kenji Hasegawa; Osamu Kurimura; Takehiko Hiramoto; Masahide Takii; Masanori Higuchi; Takaoki Ohyama; Katsuhiko Furuumi; Tsuneo Ishibashi; Masahiro Takamoto; Yasuko Harada; Susumu Harada; Kohei Hara; Hironobu Koga; Yoshiaki Ri; Taiji Masuyama; Masahiko Yoshimoto; Kazunori Shimoguchi; Kazuhiro Okuno; Kiyoyasu Fukushima; Keizo Matsumoto; Tsuyoshi Nagatake; Kazunori Oishi; Akihiro Hori; Tasuku Sakamoto; Hirofumi Tanaka; Toshihiro Morito; Mikio Fujishita; Masayuki Ando; Moritaka Suga; Naoki Saita; Masaru Nasu; Tohru Yamasaki; Jun Goto; Kazuo Kitagawa; Atsushi Saito; Hiroshi Fukuhara; Isoko Owan; Jun Inadome; Nobuya Ogawa; Koichi Deguchi

doi:10.11553/antibiotics1968b.48.449

A comparative study of tazobactam/piperacillin and piperacillin in bacterial pneumonia

Kotaro Oizumi, Takayosi Ohno, Masao Kawahara, Shinzo Kawaguchi, Masazumi Saisho, Yoshiyuki Mitutake, Akira Saito, Masumi Tomizawa, Takao Koike, Kazuo Takebe, Toyokazu Tamura, Hiroshi Inoue, Kazuki Konishi, Takashi Mohri, Sakura Katoh, Kenichi Takeuchi, Akiho Ohara, Haruhito Hirano, Hideki Ikeda, Kunio SiratoYasuo Tanno, Masato Tohno, Yasuo Ono, Takuya Suzuki, Masahiro Sakamoto, Akira Watanabe, Toshihiro Nukiwa, Kiyoshi Konno, Kuniharu Shida, Tsuneo Sayama, Kazuo Sato, Yoshiyuki Anzai, Yoshiki Anazawa, Susumu Yoshida, Akira Ohishi, Kohtaro Kaneko, Kaoru Shimada, Yasuyuki Sano, Norihisa Akiyama, Yasuo Arai, Mamoru Ohtomo, Koichiro Nakada, Tatsuo Nakatani, Naohiko Tyonabayashi, Koichiro Kudo, Hiroko Arioka, Harumi Shishido, Atsushi Takahashi, Atsuhisa Tamura, Hirofumi Katayama, Motoo Baba, Masaru Koyama, Kohji Murabayashi, Jingoro Shimada, Shoichiro Irimajiri, Yasuo Matsuoka, Mitsuo Obana, Fumio Matsumoto, Takeo Imai, Shigeki Odagiri, Takashi Oguri, Yoshihiro Hirai, Masaaki Arakawa, Shigeyuki Hoshino, Hiroki Tsukada, Nobuki Aoki, Saburo Izumi, Atsuhiko Sato, Tadakazu Hattori, Yutaka Nakano, Kenzo Takagi, Yasunobu Noda, Hideo Gonda, Toshihiko Takeuchi, Yasuo Yamada, Hidekazu Hanaki, Makoto Kawakami, Toshiyuki Yamamoto, Kanzo Suzuki, Toshinobu Yamamoto, Fumiyuki Kuze, Kenji Bando, Shinichiro Ohyama, Shohei Kusaka, Tadashi Ishida, Yoshiro Mochizuki, Rieko Kanan, Kazushige Tsuyuguchi, Kojiro Yasunaga, Seibun Yonezu, Yoshitaka Yamanaka, Nobuhiro Narita, Masayoshi Sawaki, Keiichi Mikasa, Kazuya Higashino, Takashi Nakano, Tetsuya Nishigaki, Yumiko Goto, Hiroshi Sugimoto, Rinzo Soejima, Yoshihito Niki, Osamu Moriya, Akihisa Shindo, Toshiharu Matsushima, Makoto Kimura, Michio Yamakido, Kenji Hasegawa, Osamu Kurimura, Takehiko Hiramoto, Masahide Takii, Masanori Higuchi, Takaoki Ohyama, Katsuhiko Furuumi, Tsuneo Ishibashi, Masahiro Takamoto, Yasuko Harada, Susumu Harada, Kohei Hara, Hironobu Koga, Yoshiaki Ri, Taiji Masuyama, Masahiko Yoshimoto, Kazunori Shimoguchi, Kazuhiro Okuno, Kiyoyasu Fukushima, Keizo Matsumoto, Tsuyoshi Nagatake, Kazunori Oishi, Akihiro Hori, Tasuku Sakamoto, Hirofumi Tanaka, Toshihiro Morito, Mikio Fujishita, Masayuki Ando, Moritaka Suga, Naoki Saita, Masaru Nasu, Tohru Yamasaki, Jun Goto, Kazuo Kitagawa, Atsushi Saito, Hiroshi Fukuhara, Isoko Owan, Jun Inadome, Nobuya Ogawa, Koichi Deguchi

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

The efficacy, safety and usefulness of tazobactam/piperacillin (TAZ/PIPC), in bacterial pneumonia and lung abscess were determined with PIPC as the control in a multi-institutional comparative study a penicillin antibiotic for injection prepared by combining a newly developed β-lactamase inhibitor, tazobactam (TAZ), with a broad spectrum penicillin antibiotic, piperacillin (PIPC), at a ratio of 1:4. TAZ/PIPC was intravenously injected at a dose of 2.5 g (titer) twice a day, and PIPC at a dose of 2.0 g (titer) twice a day as a rule for 14 days. The following results were obtained: 1. The efficacy rates for bacterial pneumonia and lung abscess were 94% (80/85) in TAZ/PIPC group and 89% (70/79) in PIPC group, showing no significant difference between the two groups. 2. In a comparison of degrees of improvement in clinical symptoms, signs and laboratory findings, there were no significant differences between the two groups except for results on thoracic rales after three days of administration. 3. As for bacteriological effects, the elimination rates of causative organisms were 98% (40/41) in the TAZ/PIPC group and 80% (28/35) in the PIPC group. Thus, the TAZ/PIPC group was significantly superior to the PIPC group. The TAZ/PIPC group showed significantly better eradication of bacateria as well. Bacteria considered to be pyogenic were detected in 80 patients (43 administered TAZ/PIPC and 37 administered PIPC), but β-lactamase production was confirmed in only 11 patients of each group. There were no significant differences in bacteriological effects among these patients. Minimum inhibitory concentrations of TAZ/PIPC against β-lactamase producing organisms were distinctly superior to those of PIPC. 4. Side effects occurred in 10% (10/96) of the TAZ/PIPC group and 7% (7/95) of the PIPC group. Abnormal clinical laboratory test values were observed in 22% (20/92) of the TAZ/PIPC group and 18% (17/93) of the PIPC group. Thus, there were no significant differences between the two administration groups. 5. The usefulness rate in the TAZ/PIPC group was 87% (75/86) and it was 85% (67/79) in the PIPC group, showing no significant difference between them. The results suggest that TAZ/PIPC administered at a dose of 2.5 g (titer) twice a day is more useful than PIPC administered at a dose of 2.0 g (titer) twice a day in the treatment of bacterial pneumonia.

Original language	English
Pages (from-to)	449-481
Number of pages	33
Journal	The Japanese Journal of Antibiotics
Volume	48
Issue number	4
DOIs	https://doi.org/10.11553/antibiotics1968b.48.449
Publication status	Published - 1995 Apr
Externally published	Yes

ASJC Scopus subject areas

Microbiology (medical)
Pharmacology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11553/antibiotics1968b.48.449

Cite this

Oizumi, K., Ohno, T., Kawahara, M., Kawaguchi, S., Saisho, M., Mitutake, Y., Saito, A., Tomizawa, M., Koike, T., Takebe, K., Tamura, T., Inoue, H., Konishi, K., Mohri, T., Katoh, S., Takeuchi, K., Ohara, A., Hirano, H., Ikeda, H., ... Deguchi, K. (1995). A comparative study of tazobactam/piperacillin and piperacillin in bacterial pneumonia. The Japanese Journal of Antibiotics, 48(4), 449-481. https://doi.org/10.11553/antibiotics1968b.48.449

Oizumi, K, Ohno, T, Kawahara, M, Kawaguchi, S, Saisho, M, Mitutake, Y, Saito, A, Tomizawa, M, Koike, T, Takebe, K, Tamura, T, Inoue, H, Konishi, K, Mohri, T, Katoh, S, Takeuchi, K, Ohara, A, Hirano, H, Ikeda, H, Sirato, K, Tanno, Y, Tohno, M, Ono, Y, Suzuki, T, Sakamoto, M, Watanabe, A, Nukiwa, T, Konno, K, Shida, K, Sayama, T, Sato, K, Anzai, Y, Anazawa, Y, Yoshida, S, Ohishi, A, Kaneko, K, Shimada, K, Sano, Y, Akiyama, N, Arai, Y, Ohtomo, M, Nakada, K, Nakatani, T, Tyonabayashi, N, Kudo, K, Arioka, H, Shishido, H, Takahashi, A, Tamura, A, Katayama, H, Baba, M, Koyama, M, Murabayashi, K, Shimada, J, Irimajiri, S, Matsuoka, Y, Obana, M, Matsumoto, F, Imai, T, Odagiri, S, Oguri, T, Hirai, Y, Arakawa, M, Hoshino, S, Tsukada, H, Aoki, N, Izumi, S, Sato, A, Hattori, T, Nakano, Y, Takagi, K, Noda, Y, Gonda, H, Takeuchi, T, Yamada, Y, Hanaki, H, Kawakami, M, Yamamoto, T, Suzuki, K, Yamamoto, T, Kuze, F, Bando, K, Ohyama, S, Kusaka, S, Ishida, T, Mochizuki, Y, Kanan, R, Tsuyuguchi, K, Yasunaga, K, Yonezu, S, Yamanaka, Y, Narita, N, Sawaki, M, Mikasa, K, Higashino, K, Nakano, T, Nishigaki, T, Goto, Y, Sugimoto, H, Soejima, R, Niki, Y, Moriya, O, Shindo, A, Matsushima, T, Kimura, M, Yamakido, M, Hasegawa, K, Kurimura, O, Hiramoto, T, Takii, M, Higuchi, M, Ohyama, T, Furuumi, K, Ishibashi, T, Takamoto, M, Harada, Y, Harada, S, Hara, K, Koga, H, Ri, Y, Masuyama, T, Yoshimoto, M, Shimoguchi, K, Okuno, K, Fukushima, K, Matsumoto, K, Nagatake, T, Oishi, K, Hori, A, Sakamoto, T, Tanaka, H, Morito, T, Fujishita, M, Ando, M, Suga, M, Saita, N, Nasu, M, Yamasaki, T, Goto, J, Kitagawa, K, Saito, A, Fukuhara, H, Owan, I, Inadome, J, Ogawa, N & Deguchi, K 1995, 'A comparative study of tazobactam/piperacillin and piperacillin in bacterial pneumonia', The Japanese Journal of Antibiotics, vol. 48, no. 4, pp. 449-481. https://doi.org/10.11553/antibiotics1968b.48.449

@article{4249f768f98248d3b1216d2101a00a92,

title = "A comparative study of tazobactam/piperacillin and piperacillin in bacterial pneumonia",

abstract = "The efficacy, safety and usefulness of tazobactam/piperacillin (TAZ/PIPC), in bacterial pneumonia and lung abscess were determined with PIPC as the control in a multi-institutional comparative study a penicillin antibiotic for injection prepared by combining a newly developed β-lactamase inhibitor, tazobactam (TAZ), with a broad spectrum penicillin antibiotic, piperacillin (PIPC), at a ratio of 1:4. TAZ/PIPC was intravenously injected at a dose of 2.5 g (titer) twice a day, and PIPC at a dose of 2.0 g (titer) twice a day as a rule for 14 days. The following results were obtained: 1. The efficacy rates for bacterial pneumonia and lung abscess were 94% (80/85) in TAZ/PIPC group and 89% (70/79) in PIPC group, showing no significant difference between the two groups. 2. In a comparison of degrees of improvement in clinical symptoms, signs and laboratory findings, there were no significant differences between the two groups except for results on thoracic rales after three days of administration. 3. As for bacteriological effects, the elimination rates of causative organisms were 98% (40/41) in the TAZ/PIPC group and 80% (28/35) in the PIPC group. Thus, the TAZ/PIPC group was significantly superior to the PIPC group. The TAZ/PIPC group showed significantly better eradication of bacateria as well. Bacteria considered to be pyogenic were detected in 80 patients (43 administered TAZ/PIPC and 37 administered PIPC), but β-lactamase production was confirmed in only 11 patients of each group. There were no significant differences in bacteriological effects among these patients. Minimum inhibitory concentrations of TAZ/PIPC against β-lactamase producing organisms were distinctly superior to those of PIPC. 4. Side effects occurred in 10% (10/96) of the TAZ/PIPC group and 7% (7/95) of the PIPC group. Abnormal clinical laboratory test values were observed in 22% (20/92) of the TAZ/PIPC group and 18% (17/93) of the PIPC group. Thus, there were no significant differences between the two administration groups. 5. The usefulness rate in the TAZ/PIPC group was 87% (75/86) and it was 85% (67/79) in the PIPC group, showing no significant difference between them. The results suggest that TAZ/PIPC administered at a dose of 2.5 g (titer) twice a day is more useful than PIPC administered at a dose of 2.0 g (titer) twice a day in the treatment of bacterial pneumonia.",

author = "Kotaro Oizumi and Takayosi Ohno and Masao Kawahara and Shinzo Kawaguchi and Masazumi Saisho and Yoshiyuki Mitutake and Akira Saito and Masumi Tomizawa and Takao Koike and Kazuo Takebe and Toyokazu Tamura and Hiroshi Inoue and Kazuki Konishi and Takashi Mohri and Sakura Katoh and Kenichi Takeuchi and Akiho Ohara and Haruhito Hirano and Hideki Ikeda and Kunio Sirato and Yasuo Tanno and Masato Tohno and Yasuo Ono and Takuya Suzuki and Masahiro Sakamoto and Akira Watanabe and Toshihiro Nukiwa and Kiyoshi Konno and Kuniharu Shida and Tsuneo Sayama and Kazuo Sato and Yoshiyuki Anzai and Yoshiki Anazawa and Susumu Yoshida and Akira Ohishi and Kohtaro Kaneko and Kaoru Shimada and Yasuyuki Sano and Norihisa Akiyama and Yasuo Arai and Mamoru Ohtomo and Koichiro Nakada and Tatsuo Nakatani and Naohiko Tyonabayashi and Koichiro Kudo and Hiroko Arioka and Harumi Shishido and Atsushi Takahashi and Atsuhisa Tamura and Hirofumi Katayama and Motoo Baba and Masaru Koyama and Kohji Murabayashi and Jingoro Shimada and Shoichiro Irimajiri and Yasuo Matsuoka and Mitsuo Obana and Fumio Matsumoto and Takeo Imai and Shigeki Odagiri and Takashi Oguri and Yoshihiro Hirai and Masaaki Arakawa and Shigeyuki Hoshino and Hiroki Tsukada and Nobuki Aoki and Saburo Izumi and Atsuhiko Sato and Tadakazu Hattori and Yutaka Nakano and Kenzo Takagi and Yasunobu Noda and Hideo Gonda and Toshihiko Takeuchi and Yasuo Yamada and Hidekazu Hanaki and Makoto Kawakami and Toshiyuki Yamamoto and Kanzo Suzuki and Toshinobu Yamamoto and Fumiyuki Kuze and Kenji Bando and Shinichiro Ohyama and Shohei Kusaka and Tadashi Ishida and Yoshiro Mochizuki and Rieko Kanan and Kazushige Tsuyuguchi and Kojiro Yasunaga and Seibun Yonezu and Yoshitaka Yamanaka and Nobuhiro Narita and Masayoshi Sawaki and Keiichi Mikasa and Kazuya Higashino and Takashi Nakano and Tetsuya Nishigaki and Yumiko Goto and Hiroshi Sugimoto and Rinzo Soejima and Yoshihito Niki and Osamu Moriya and Akihisa Shindo and Toshiharu Matsushima and Makoto Kimura and Michio Yamakido and Kenji Hasegawa and Osamu Kurimura and Takehiko Hiramoto and Masahide Takii and Masanori Higuchi and Takaoki Ohyama and Katsuhiko Furuumi and Tsuneo Ishibashi and Masahiro Takamoto and Yasuko Harada and Susumu Harada and Kohei Hara and Hironobu Koga and Yoshiaki Ri and Taiji Masuyama and Masahiko Yoshimoto and Kazunori Shimoguchi and Kazuhiro Okuno and Kiyoyasu Fukushima and Keizo Matsumoto and Tsuyoshi Nagatake and Kazunori Oishi and Akihiro Hori and Tasuku Sakamoto and Hirofumi Tanaka and Toshihiro Morito and Mikio Fujishita and Masayuki Ando and Moritaka Suga and Naoki Saita and Masaru Nasu and Tohru Yamasaki and Jun Goto and Kazuo Kitagawa and Atsushi Saito and Hiroshi Fukuhara and Isoko Owan and Jun Inadome and Nobuya Ogawa and Koichi Deguchi",

year = "1995",

month = apr,

doi = "10.11553/antibiotics1968b.48.449",

language = "English",

volume = "48",

pages = "449--481",

journal = "The Japanese Journal of Antibiotics",

issn = "0368-2781",

number = "4",

}

TY - JOUR

T1 - A comparative study of tazobactam/piperacillin and piperacillin in bacterial pneumonia

AU - Oizumi, Kotaro

AU - Ohno, Takayosi

AU - Kawahara, Masao

AU - Kawaguchi, Shinzo

AU - Saisho, Masazumi

AU - Mitutake, Yoshiyuki

AU - Saito, Akira

AU - Tomizawa, Masumi

AU - Koike, Takao

AU - Takebe, Kazuo

AU - Tamura, Toyokazu

AU - Inoue, Hiroshi

AU - Konishi, Kazuki

AU - Mohri, Takashi

AU - Katoh, Sakura

AU - Takeuchi, Kenichi

AU - Ohara, Akiho

AU - Hirano, Haruhito

AU - Ikeda, Hideki

AU - Sirato, Kunio

AU - Tanno, Yasuo

AU - Tohno, Masato

AU - Ono, Yasuo

AU - Suzuki, Takuya

AU - Sakamoto, Masahiro

AU - Watanabe, Akira

AU - Nukiwa, Toshihiro

AU - Konno, Kiyoshi

AU - Shida, Kuniharu

AU - Sayama, Tsuneo

AU - Sato, Kazuo

AU - Anzai, Yoshiyuki

AU - Anazawa, Yoshiki

AU - Yoshida, Susumu

AU - Ohishi, Akira

AU - Kaneko, Kohtaro

AU - Shimada, Kaoru

AU - Sano, Yasuyuki

AU - Akiyama, Norihisa

AU - Arai, Yasuo

AU - Ohtomo, Mamoru

AU - Nakada, Koichiro

AU - Nakatani, Tatsuo

AU - Tyonabayashi, Naohiko

AU - Kudo, Koichiro

AU - Arioka, Hiroko

AU - Shishido, Harumi

AU - Takahashi, Atsushi

AU - Tamura, Atsuhisa

AU - Katayama, Hirofumi

AU - Baba, Motoo

AU - Koyama, Masaru

AU - Murabayashi, Kohji

AU - Shimada, Jingoro

AU - Irimajiri, Shoichiro

AU - Matsuoka, Yasuo

AU - Obana, Mitsuo

AU - Matsumoto, Fumio

AU - Imai, Takeo

AU - Odagiri, Shigeki

AU - Oguri, Takashi

AU - Hirai, Yoshihiro

AU - Arakawa, Masaaki

AU - Hoshino, Shigeyuki

AU - Tsukada, Hiroki

AU - Aoki, Nobuki

AU - Izumi, Saburo

AU - Sato, Atsuhiko

AU - Hattori, Tadakazu

AU - Nakano, Yutaka

AU - Takagi, Kenzo

AU - Noda, Yasunobu

AU - Gonda, Hideo

AU - Takeuchi, Toshihiko

AU - Yamada, Yasuo

AU - Hanaki, Hidekazu

AU - Kawakami, Makoto

AU - Yamamoto, Toshiyuki

AU - Suzuki, Kanzo

AU - Yamamoto, Toshinobu

AU - Kuze, Fumiyuki

AU - Bando, Kenji

AU - Ohyama, Shinichiro

AU - Kusaka, Shohei

AU - Ishida, Tadashi

AU - Mochizuki, Yoshiro

AU - Kanan, Rieko

AU - Tsuyuguchi, Kazushige

AU - Yasunaga, Kojiro

AU - Yonezu, Seibun

AU - Yamanaka, Yoshitaka

AU - Narita, Nobuhiro

AU - Sawaki, Masayoshi

AU - Mikasa, Keiichi

AU - Higashino, Kazuya

AU - Nakano, Takashi

AU - Nishigaki, Tetsuya

AU - Goto, Yumiko

AU - Sugimoto, Hiroshi

AU - Soejima, Rinzo

AU - Niki, Yoshihito

AU - Moriya, Osamu

AU - Shindo, Akihisa

AU - Matsushima, Toshiharu

AU - Kimura, Makoto

AU - Yamakido, Michio

AU - Hasegawa, Kenji

AU - Kurimura, Osamu

AU - Hiramoto, Takehiko

AU - Takii, Masahide

AU - Higuchi, Masanori

AU - Ohyama, Takaoki

AU - Furuumi, Katsuhiko

AU - Ishibashi, Tsuneo

AU - Takamoto, Masahiro

AU - Harada, Yasuko

AU - Harada, Susumu

AU - Hara, Kohei

AU - Koga, Hironobu

AU - Ri, Yoshiaki

AU - Masuyama, Taiji

AU - Yoshimoto, Masahiko

AU - Shimoguchi, Kazunori

AU - Okuno, Kazuhiro

AU - Fukushima, Kiyoyasu

AU - Matsumoto, Keizo

AU - Nagatake, Tsuyoshi

AU - Oishi, Kazunori

AU - Hori, Akihiro

AU - Sakamoto, Tasuku

AU - Tanaka, Hirofumi

AU - Morito, Toshihiro

AU - Fujishita, Mikio

AU - Ando, Masayuki

AU - Suga, Moritaka

AU - Saita, Naoki

AU - Nasu, Masaru

AU - Yamasaki, Tohru

AU - Goto, Jun

AU - Kitagawa, Kazuo

AU - Saito, Atsushi

AU - Fukuhara, Hiroshi

AU - Owan, Isoko

AU - Inadome, Jun

AU - Ogawa, Nobuya

AU - Deguchi, Koichi

PY - 1995/4

Y1 - 1995/4

N2 - The efficacy, safety and usefulness of tazobactam/piperacillin (TAZ/PIPC), in bacterial pneumonia and lung abscess were determined with PIPC as the control in a multi-institutional comparative study a penicillin antibiotic for injection prepared by combining a newly developed β-lactamase inhibitor, tazobactam (TAZ), with a broad spectrum penicillin antibiotic, piperacillin (PIPC), at a ratio of 1:4. TAZ/PIPC was intravenously injected at a dose of 2.5 g (titer) twice a day, and PIPC at a dose of 2.0 g (titer) twice a day as a rule for 14 days. The following results were obtained: 1. The efficacy rates for bacterial pneumonia and lung abscess were 94% (80/85) in TAZ/PIPC group and 89% (70/79) in PIPC group, showing no significant difference between the two groups. 2. In a comparison of degrees of improvement in clinical symptoms, signs and laboratory findings, there were no significant differences between the two groups except for results on thoracic rales after three days of administration. 3. As for bacteriological effects, the elimination rates of causative organisms were 98% (40/41) in the TAZ/PIPC group and 80% (28/35) in the PIPC group. Thus, the TAZ/PIPC group was significantly superior to the PIPC group. The TAZ/PIPC group showed significantly better eradication of bacateria as well. Bacteria considered to be pyogenic were detected in 80 patients (43 administered TAZ/PIPC and 37 administered PIPC), but β-lactamase production was confirmed in only 11 patients of each group. There were no significant differences in bacteriological effects among these patients. Minimum inhibitory concentrations of TAZ/PIPC against β-lactamase producing organisms were distinctly superior to those of PIPC. 4. Side effects occurred in 10% (10/96) of the TAZ/PIPC group and 7% (7/95) of the PIPC group. Abnormal clinical laboratory test values were observed in 22% (20/92) of the TAZ/PIPC group and 18% (17/93) of the PIPC group. Thus, there were no significant differences between the two administration groups. 5. The usefulness rate in the TAZ/PIPC group was 87% (75/86) and it was 85% (67/79) in the PIPC group, showing no significant difference between them. The results suggest that TAZ/PIPC administered at a dose of 2.5 g (titer) twice a day is more useful than PIPC administered at a dose of 2.0 g (titer) twice a day in the treatment of bacterial pneumonia.

AB - The efficacy, safety and usefulness of tazobactam/piperacillin (TAZ/PIPC), in bacterial pneumonia and lung abscess were determined with PIPC as the control in a multi-institutional comparative study a penicillin antibiotic for injection prepared by combining a newly developed β-lactamase inhibitor, tazobactam (TAZ), with a broad spectrum penicillin antibiotic, piperacillin (PIPC), at a ratio of 1:4. TAZ/PIPC was intravenously injected at a dose of 2.5 g (titer) twice a day, and PIPC at a dose of 2.0 g (titer) twice a day as a rule for 14 days. The following results were obtained: 1. The efficacy rates for bacterial pneumonia and lung abscess were 94% (80/85) in TAZ/PIPC group and 89% (70/79) in PIPC group, showing no significant difference between the two groups. 2. In a comparison of degrees of improvement in clinical symptoms, signs and laboratory findings, there were no significant differences between the two groups except for results on thoracic rales after three days of administration. 3. As for bacteriological effects, the elimination rates of causative organisms were 98% (40/41) in the TAZ/PIPC group and 80% (28/35) in the PIPC group. Thus, the TAZ/PIPC group was significantly superior to the PIPC group. The TAZ/PIPC group showed significantly better eradication of bacateria as well. Bacteria considered to be pyogenic were detected in 80 patients (43 administered TAZ/PIPC and 37 administered PIPC), but β-lactamase production was confirmed in only 11 patients of each group. There were no significant differences in bacteriological effects among these patients. Minimum inhibitory concentrations of TAZ/PIPC against β-lactamase producing organisms were distinctly superior to those of PIPC. 4. Side effects occurred in 10% (10/96) of the TAZ/PIPC group and 7% (7/95) of the PIPC group. Abnormal clinical laboratory test values were observed in 22% (20/92) of the TAZ/PIPC group and 18% (17/93) of the PIPC group. Thus, there were no significant differences between the two administration groups. 5. The usefulness rate in the TAZ/PIPC group was 87% (75/86) and it was 85% (67/79) in the PIPC group, showing no significant difference between them. The results suggest that TAZ/PIPC administered at a dose of 2.5 g (titer) twice a day is more useful than PIPC administered at a dose of 2.0 g (titer) twice a day in the treatment of bacterial pneumonia.

UR - http://www.scopus.com/inward/record.url?scp=0028997418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028997418&partnerID=8YFLogxK

U2 - 10.11553/antibiotics1968b.48.449

DO - 10.11553/antibiotics1968b.48.449

M3 - Article

C2 - 7783313

AN - SCOPUS:0028997418

SN - 0368-2781

VL - 48

SP - 449

EP - 481

JO - The Japanese Journal of Antibiotics

JF - The Japanese Journal of Antibiotics

IS - 4

ER -

A comparative study of tazobactam/piperacillin and piperacillin in bacterial pneumonia

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this